Literature DB >> 11507232

Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein.

E de Rosny1, R Vassell, P T Wingfield, C T Wild, C D Weiss.   

Abstract

Two heptad repeat regions in the ectodomain of the human immunodeficiency virus type 1 (HIV-1) transmembrane subunit (gp41) self-assemble into a six-helix bundle structure that is critical for virus entry. Immunizations with peptides corresponding to these regions generated antibodies specific to the receptor-activated conformations of gp41.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11507232      PMCID： PMC115132          DOI： 10.1128/jvi.75.18.8859-8863.2001

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  18 in total

1.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

2.  Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein.

Authors:  J J Wang; S Steel; R Wisniewolski; C Y Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

3.  HIV-1 inhibition by a peptide.

Authors:  S Jiang; K Lin; N Strick; A R Neurath
Journal:  Nature       Date:  1993-09-09       Impact factor: 49.962

4.  Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41.

Authors:  M K Gorny; S Zolla-Pazner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

6.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.

Authors:  B K Chen; K Saksela; R Andino; D Baltimore
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.

Authors:  C T Wild; D C Shugars; T K Greenwell; C B McDanal; T J Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  S Jiang; K Lin; M Lu
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103
View more
  20 in total

1.  Variable sensitivity to substitutions in the N-terminal heptad repeat of Mason-Pfizer monkey virus transmembrane protein.

Authors:  Chisu Song; Eric Hunter
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

2.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

3.  Protein grafting of an HIV-1-inhibiting epitope.

Authors:  Samuel K Sia; Peter S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

4.  Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.

Authors:  Eve de Rosny; Russell Vassell; Shibo Jiang; Renate Kunert; Carol D Weiss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

5.  Conformational changes in HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion and inactivation.

Authors:  Antony S Dimitrov; John M Louis; Carole A Bewley; G Marius Clore; Robert Blumenthal
Journal:  Biochemistry       Date:  2005-09-20       Impact factor: 3.162

6.  Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy.

Authors:  Qian Wang; Wenwen Bi; Xiaojie Zhu; Haoyang Li; Qianqian Qi; Fei Yu; Lu Lu; Shibo Jiang
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

7.  Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion.

Authors:  Catherine M Finnegan; Werner Berg; George K Lewis; Anthony L DeVico
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.

Authors:  Hongtao Wang; Zhi Qi; Angi Guo; Qinchao Mao; Hong Lu; Xiuli An; Chenglai Xia; Xiaojuan Li; Asim K Debnath; Shuguang Wu; Shuwen Liu; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

9.  Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Authors:  Abdul S Yunus; Trent P Jackson; Katherine Crisafi; Irina Burimski; Nicole R Kilgore; Dorian Zoumplis; Graham P Allaway; Carl T Wild; Karl Salzwedel
Journal:  Virology       Date:  2009-11-18       Impact factor: 3.616

10.  AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts.

Authors:  Simone Giannecchini; Patrizia Isola; Olimpia Sichi; Donatella Matteucci; Mauro Pistello; Lucia Zaccaro; Daniela Del Mauro; Mauro Bendinelli
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.